Savara Inc

Savara Inc.

Biotechnology Healthcare Langhorne, PA, United States SVRA (NMS)

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Other Biotechnology Companies

View All →

Frequently Asked Questions

Has Savara Inc had layoffs?
No layoff events have been recorded for Savara Inc in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Savara Inc have?
Savara Inc has approximately 59 employees.
What industry is Savara Inc in?
Savara Inc operates in the Biotechnology industry, within the Healthcare sector.
Is Savara Inc a publicly traded company?
Yes, Savara Inc is publicly traded under the ticker symbol SVRA on the NMS. The company has a market capitalization of approximately $1.29 billion.
Where is Savara Inc headquartered?
Savara Inc is headquartered in Langhorne, PA, United States at 1717 Langhorne Newtown Road, Langhorne, PA 19047, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.